Abstract
With almost universal virological recurrence and a projected several-fold increase in HCV-related end-stage liver disease within the next decade, a clear understanding of the natural history of posttransplant HCV infection and optimization of the management of recurrent HCV infection are imperative. This article describes the natural history, risk factors, and current strategies for the amelioration of posttransplant HCV infection.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Disease Progression
-
Hepacivirus / pathogenicity*
-
Hepatitis C, Chronic / drug therapy
-
Hepatitis C, Chronic / pathology*
-
Hepatitis C, Chronic / therapy*
-
Humans
-
Immunoglobulins / therapeutic use
-
Interferon alpha-2
-
Interferon-alpha / therapeutic use
-
Kidney Failure, Chronic / pathology
-
Kidney Failure, Chronic / virology
-
Liver Transplantation*
-
Polyethylene Glycols / therapeutic use
-
Recombinant Proteins
-
Recurrence
-
Ribavirin / therapeutic use
Substances
-
Immunoglobulins
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Polyethylene Glycols
-
Ribavirin
-
peginterferon alfa-2a